- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00779285
Safety Study of CAELYX in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines (Study P04057)(TERMINATED)
June 18, 2015 updated by: Merck Sharp & Dohme LLC
Cardiac Safety Profile of Caelyx Therapy in Anthracyclin Pretreated Metastatic Breast Cancer Patients.
The purpose of this study is to evaluate the cardiac safety of Caelyx in patients with metastatic breast cancer who have previously received chemotherapy with anthracyclines.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
1
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Women with histologically or cytologically confirmed metastatic breast cancer (no prior chemotherapy for metastatic disease).
- Prior treatment with an anthracyclin-containing regimen in the adjuvant setting (cumulative dose >240mg/m^2 and <360mg/m^2 doxorubicin or >430mg/m^2 and <650mg/m^2 epirubicin).
- Women >18 years of age.
- Documented measurable and/or evaluable metastatic breast cancer by appropriate radiological imaging (computed tomography (CT) scan and/or magnetic resonance imaging (MRI)).
- Performance status of at least 60% (Karnofsky index) and a life expectancy of at least 12 weeks.
- Left ventricular ejection fraction >50%.
Normal organ function, except if abnormal due to tumor involvement.
Adequate bone marrow function as indicated:
- Platelets >100,000/mm^3
- Hemoglobin >9 g/dL
- Neutrophils >1,500/mm^3
Adequate renal function as indicated by:
- Serum Creatinine <1.5 x the upper limit of normal
Adequate liver function, as indicated by:
- Bilirubin and aspartate aminotransferase (AST) or alanine aminotransferase (ALT) <2 times upper limit of normal (<4 times upper limit of normal when related to primary disease)
- Subjects must be capable to demonstrate their willingness to participate in the study and comply with its procedures by signing a written informed consent.
- Women of childbearing potential (includes women who are less than 1 year postmenopausal and women who become sexually active) must be using an acceptable method of birth control (e.g., hormonal contraceptive, medically prescribed intrauterine device (IUD), condom in combination with spermicide) or be surgically sterilized (e.g., hysterectomy or tubal ligation).
- Subjects must understand and be able to adhere to the dosing and visit schedules.
Exclusion Criteria:
- Patient is pregnant or is breastfeeding.
- Patients with moderate or severe heart failure (New York Heart Association (NYHA) class III/IV).
- Hypersensitivity to anthracycline therapy or a history of severe hypersensitivity reactions to products containing Cremophor® EL (e.g., cyclosporin for injection concentrate and teniposide for injection concentrate).
- Prior chemotherapy for metastatic disease.
- Clinically significant hepatic disease (except liver metastases of primary disease).
- Uncontrolled bacterial, viral, or fungal infection.
- Radiotherapy in the last 4 weeks or prior radiation therapy to more than one-third of the hemopoietic sites.
- Any other currently known malignancy or pre-malignant lesions or any history of other malignancy within the past five years (except non-melanoma skin cancer and surgically cured cervical cancer).
- Symptomatic brain metastasis.
- Patients who are incapacitated, largely or wholly bedridden or confined to a wheelchair, and who have little or no ability for self-care.
- Current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, endocrine, pulmonary, cardiac, neurological or cerebral disease.
- Documented human immunodeficiency virus (HIV) infection.
- Any condition (medical, social, psychological) which would prevent adequate follow-up.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Single-arm
Pegylated Lyposomal Doxorubicin (Caelyx) 50 mg/m2, given for 6 cycles
|
Pegylated Liposomal Doxorubicin (Caelyx) IV, 50 mg/m2 once every 4 weeks for 6 cycles or until disease progression, whichever is earlier.
Patients still receiving clinical benefit after a total of 6 cycles of Caelyx, may continue therapy at the discretion of the investigator.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cardiac Events
Time Frame: Every 4 weeks during 6 cycles.
|
A cardiac event was defined as a decrease in left ventricular ejection fraction (LVEF) of >=20 points from baseline if the resting LVEF remained in the normal range, or a decrease of >=10 points if the LVEF became abnormal (lower than the institutional lower limit of normal).
|
Every 4 weeks during 6 cycles.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2006
Primary Completion (ACTUAL)
August 1, 2006
Study Completion (ACTUAL)
August 1, 2006
Study Registration Dates
First Submitted
October 23, 2008
First Submitted That Met QC Criteria
October 23, 2008
First Posted (ESTIMATE)
October 24, 2008
Study Record Updates
Last Update Posted (ESTIMATE)
July 14, 2015
Last Update Submitted That Met QC Criteria
June 18, 2015
Last Verified
June 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P04057
- EUDRACT NO. 2004-001177-25
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Neoplasm
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...Not yet recruitingBreast Cancer | Neoplasm, Breast | Malignant Neoplasm of Breast | Breast Tumor | Mammary Cancer | Mammary Neoplasms, Human | Tumor, Breast | Mammary NeoplasmUnited States
-
National Cancer Institute (NCI)RecruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Triple-Negative Breast CarcinomaUnited States
-
Jonsson Comprehensive Cancer CenterU.S. Army Medical Research and Development Command; U.S. Army Medical Research...CompletedBreast Carcinoma | Malignant Breast Neoplasm | Benign Breast NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | HER2-Positive Breast CarcinomaUnited States
-
Indiana UniversityIndiana University HealthCompletedBreast Cancer | Breast Neoplasms | Anxiety | Breast Carcinoma | Fear | Cancer of Breast | Malignant Tumor of Breast | Malignant Neoplasm of Breast | Mammary Cancer | Human Mammary Carcinoma | Mammary Neoplasm, Human | Mammary Carcinoma | Neoplasm Remission, Spontaneous | Spontaneous Neoplasm Regression | Regression,... and other conditionsUnited States
-
National Cancer Institute, ThailandCompleted
-
Umbria Bioengineering TechnologiesToscana Life Sciences Sviluppo s.r.l.; London South Bank University; ELAROS 24... and other collaboratorsRecruitingWomen's Health: Neoplasm of BreastItaly, Spain, Poland, Portugal, Switzerland
-
Istanbul Aydın UniversityActive, not recruiting
-
University of OviedoCompletedWomen's Health: Neoplasm of BreastSpain
-
National Cancer Institute, ThailandCompleted
Clinical Trials on Pegylated Liposomal Doxorubicin
-
Sun Yat-sen UniversityUnknown
-
GlaxoSmithKlineCompletedNeoplasms, OvarianUnited States
-
MedSIRRoche Pharma AG; ExperiorCompleted
-
National Cancer Institute (NCI)CompletedRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Male Breast Carcinoma | Stage IV Breast Cancer AJCC...United States
-
National Cancer Institute (NCI)CompletedDS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell MyelomaUnited States
-
Fudan UniversityRecruiting
-
Cancer Institute and Hospital, Chinese Academy...CSPC Ouyi Pharmaceutical Co., Ltd.UnknownHER2-positive Breast CancerChina
-
ARCAGY/ GINECO GROUPCompleted
-
European Organisation for Research and Treatment...CompletedBreast CancerFrance, Spain, Netherlands, United Kingdom, Italy, Israel, Switzerland, Greece, Austria
-
University of ArizonaTerminatedBreast CancerUnited States